Answers are grounded in this paper and cite their sources.
The artificial pancreas device system (APDS), which combines continuous glucose monitoring, insulin pumps, and control algorithms, can improve glycemic control. As these technologies advance, clinical trial design becomes more complex. We compared selected guidelines from the United States, China, and South Korea on clinical trials for APDS and its components, using EU guideline as a supplementary reference. A predefined framework covered ten trial design items. Seven guidelines were included: two from the United States, one each from China and South Korea, and three from the EU. The guidelines differed in scope and detail. U.S. FDA guideline addressed APDS and digital health technologies, while the Chinese and South Korean guidelines focused on continuous glucose monitoring and insulin pumps, respectively. Differences were most apparent in system and component evaluation, trial design flexibility, patient-related factors, and clinical development stages. The U.S. guidelines covered both the integrated system and its components and provided more detail on these areas. The Chinese and South Korean guidelines focused on individual components and set more structured trial requirements. EU guideline addressed lifecycle management, investigation stages, design flexibility, and safety assessment. The findings reflect differences in the scope, requirements, and recommendations of the selected guidelines, rather than indicating that one approach to APDS clinical trial design is preferable. Together with the technical characteristics of APDS and its components, these differences may influence clinical trial design and resulting clinical evidence. Understanding them may help inform the planning and adaptation of APDS clinical trials planning and adaptation across countries.
No takes yet. Share an insight, caveat, or question.
姚蒙 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: